Embed Size (px)
Citation preview
Rob Camp28 June 2018
EUPATI WEBINAR
Community Advisory BoardsQuick Introduction
European Patients’ Academy on Therapeutic Innovation
§ The European Community Advisory Board (ECAB) was established in 1997 as a forum for interaction between the community of people living with HIV and AIDS (PLWHA) and the pharmaceutical industry.
§ ECAB operates as a working group of the European AIDS Treatment Group (EATG), a European voluntary patient organisation for PLWHA.
§ At the end of 2016 ECAB had 112 members. The membership covers a total of approximately 38 countries.
2
European Patients’ Academy on Therapeutic Innovation
§ A group of patients who offer their expertise to public or private sponsors of clinical research Ø Overall programme development
Ø A single clinical trial
Ø Other aspects beyond the research programme
§ The same group of patients advises several sponsors in their field Ø Avoids selection of patients’ representatives by the sponsor
§ Agenda and secretariat driven by the patients
3
A Community Advisory Board is
European Patients’ Academy on Therapeutic Innovation
4
Same disease area, different sponsors
Sponsor
AAdvisors
(clinicians)Advisors
(patients)
Sponsor
BAdvisors
(clinicians)Advisors
(pa>ents)
Sponsor
CAdvisors
(clinicians)Advisors
(patients)
Advisors (patients)
Sponsor
ASponsor
B
Sponsor
C clinicians
CAB modelSponsor-dependant model
European Patients’ Academy on Therapeutic Innovation
5
SCOPE
§ Also Community Relations (DSMBs, Investigator Meetings), marketing practices and publicity…
Trial protocolAll aspects, not just informedconsent
Strategy trials
Collaboration with competitors
Compassionate use programme
Pipeline drug developmentportfolio and plan
Reasonable pricingWorld-wide AccessPatent availability to generics companies
European Patients’ Academy on Therapeutic Innovation
§ Shorten the development time § More patient-friendly PROMs§ Faster recruitment/less drop-outs § Registries§ Disease environment
Ø Real-life experience + social responsibility
§ Higher quality resultsØ Faster approval + market access.
6
Value
European Patients’ Academy on Therapeutic Innovation
§ October European Round Table of Companies meeting Barcelona - the value of listening to patients early
§ CFE, Duchenne, TSC§ [email protected], [email protected]
7
Forward ho!
